Diet and Weight Loss Improves Psoriatic Arthritis

Save

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

RheumNow Podcast – Gout Spot Light (1.11.19)

Save

Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:

2018 Rheumatology Year In Review

Save

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likel

Best of 2018: The Safety of Paternal Exposure to DMARDs and Biologics

Save

Pregnancy and drug safety is a complex issue, often with limited information about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

Best of 2018: Ustekinumab May be Effective in Lupus

Save

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory param

RheumNow Podcast – Rheumatologist Salaries (12.21.18)

Save

Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Save

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

Save

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Save

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

RheumNow Podcast – Can RA Be Prevented (12.7.18)

Save

Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

Save

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues inclu

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Save

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.

RheumNow Podcast – To Needle or Not to Needle (11.30.18)

Save

Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:

CIRT Trial - Methotrexate Fails at Cardiovascular Prevention

Save

Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.

RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)

Save

Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com.  Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Save

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

Save

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)

Save

This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups.  ACR 2018 highlights for me included:

Updates on Psoriatic Arthritis at ACR 2018

Save

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

Save

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria